The association between radiographic spinal progression (mSASSS change score) and NSAID intake in patients with axSpA in multivariable longitudinal GEE
| All axSpA β (95% CI)* (n=461) | nr-axSpA β (95% CI)*(n=244) | r-axSpA β (95% CI)* (n=217) | |
|---|---|---|---|
| NSAID intake score, per 10 points | -0.04 (-0.09, 0.00) | -0.02 (-0.06, 0.02) | -0.07 (-0.13, 0.00) |
| NSAID type§ | |||
| NS inhibitors vs No NSAID | 0.30(-0.07, 0.66) | 0.25(-0.07, 0.57) | 0.26(-0.40, 0.92) |
| COX2i vs No NSAID | 0.17(-0.19, 0.54) | 0.15(-0.15, 0.46) | 0.18(-0.49, 0.85) |
| COX2i vs NS inhibitors | -0.12(-0.37, 0.12) | -0.10(-0.28, 0.09) | -0.08(-0.57, 0.40) |
| Analysis stratified according to NSAID type | |||
| Non-selective NSAID intake score, per 10 points | -0.06(-0.12, 0.00) | -0.04(-0.09, 0.01) | -0.07(-0.17, 0.03) |
| COX2 selective NSAID intake score, per 10 points | -0.06(-0.13, 0.02) | -0.03(-0.07, 0.02) | -0.09(-0.18, 0.01) |
axSpA: axial spondyloarthritis; COX2i, cyclooxygenase-2 selective inhibitors; n, number of current 2-year radiographic intervals in multivariable analyses; NS, non-selective COXi; NSAID, non-steroidal anti-inflammatory drugs.
*All multivariable models were adjusted for sex, symptom duration at the beginning of the interval, time-averaged ASDAS the interval, classification as radiographic axSpA, smoking in the interval, mSASSS at the beginning of theinterval, and TNFi use in the interval.
§NSAID intake score was added in this model.